Literature DB >> 11399978

Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes.

P Costa1, S Rusconi, D Mavilio, M Fogli, G Murdaca, D Pende, M C Mingari, M Galli, L Moretta, A De Maria.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) is associated with a decrease in viral replication to undetectable levels and with an increase in CD4 T lymphocytes. Residual HIV-1 replication occurs together with incomplete recovery of cytotoxic CD8 T lymphocyte (CTL) numbers and function. We sought to determine whether expression of HLA class I-specific inhibitory natural killer receptors (iNKR) on the CTL of patients who had been treated successfully with HAART for 24 months could be involved, at least in part, in residual CTL functional inhibition.
METHODS: Two-colour cytofluorometry was used to analyse the expression of six different iNKR including p58.1, p58.2, p70, p140, CD94/NKG2A and LIR1/ILT2 on the CD3, CD8 lymphocytes of eight patients with successful long-term suppression of viral replication before and after 3, 6 and 24 months of HAART. Healthy subjects were analysed as controls. HIV-1-specific cytotoxic activity was determined after 24 months of HAART in the presence and absence of iNKR-masking.
RESULTS: No significant reduction of iNKR expression on CD8 T cells was observed by 6 months. Expression of p70 and p140 was inversely correlated with the increasing CD4 numbers. After 24 months CD8 T-lymphocytes expressing p58.1, p58.2, p70, p140 and CD94/NKG2A returned to levels indistinguishable from those of the healthy controls. A significantly increased proportion of CD8 CTL still expressed LIR1/ILT2, a receptor with broad HLA-class I specificity. Functional analysis of freshly separated cells revealed that the disruption of the interaction between LIR1/ILT2 and HLA-class I could partly restore HIV-1-specific lysis.
CONCLUSIONS: A decrease in CD3CD8iNKR cells is observed beyond 6 months of HAART. In some patients functional impairment due to LIR1/ILT2 expression may persist even after 24 months of successful HAART.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399978     DOI: 10.1097/00002030-200105250-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

2.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

3.  Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA).

Authors:  Keigo Hayashi; Ken-Ei Sada; Yosuke Asano; Yu Katayama; Keiji Ohashi; Michiko Morishita; Yoshia Miyawaki; Haruki Watanabe; Takayuki Katsuyama; Mariko Narazaki; Yoshinori Matsumoto; Nobuyuki Yajima; Ryusuke Yoshimi; Yasuhiro Shimojima; Shigeru Ohno; Hiroshi Kajiyama; Kunihiro Ichinose; Shuzo Sato; Michio Fujiwara; Jun Wada
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

4.  Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function.

Authors:  M Nedim Ince; Brooke Harnisch; Zhan Xu; Sang-Kyung Lee; Christoph Lange; Lorenzo Moretta; Michael Lederman; Judy Lieberman
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

5.  Differential induction of CD94 and NKG2 in CD4 helper T cells. A consequence of influenza virus infection and interferon-gamma?

Authors:  Christine M Graham; Jillian R Christensen; D Brian Thomas
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

6.  Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.

Authors:  P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions.

Authors:  Kang Yu; Chelsea L Davidson; Agnieszka Wójtowicz; Luiz Lisboa; Ting Wang; Adriana M Airo; Jean Villard; Jeremie Buratto; Tatyana Sandalova; Adnane Achour; Atul Humar; Katia Boggian; Alexia Cusini; Christian van Delden; Adrian Egli; Oriol Manuel; Nicolas Mueller; Pierre-Yves Bochud; Deborah N Burshtyn
Journal:  J Clin Invest       Date:  2018-03-12       Impact factor: 14.808

8.  A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.

Authors:  Fabio Morandi; Elisa Ferretti; Paola Bocca; Ignazia Prigione; Lizzia Raffaghello; Vito Pistoia
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

9.  Systemic and Intestinal Viral Reservoirs in CD4+ T Cell Subsets in Primary SIV Infection.

Authors:  Xiaolei Wang; Widade Ziani; Ronald S Veazey; Huanbin Xu
Journal:  Viruses       Date:  2021-11-30       Impact factor: 5.048

10.  Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).

Authors:  John E McKinnon; Robbie B Mailliard; Susan Swindells; Timothy J Wilkin; Luann Borowski; Jillian M Roper; Barbara Bastow; Mary Kearney; Ann Wiegand; John W Mellors; Charles R Rinaldo
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.